Vanguard Group Inc P Lx Pharma Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.12 - $0.3 $5,931 - $14,828	-49,428 Reduced 14.6%	289,094 $37,000
Q4 2022 Feb 10, 2023	SELL	$0.15 - $0.63 $116,592 - $489,688	-777,284 Reduced 69.66%	338,522 $54,000
Q3 2022 Nov 14, 2022	BUY	$0.52 - $3.08 $7,776 - $46,058	14,954 Added 1.36%	1,115,806 $726,000
Q1 2022 May 13, 2022	SELL	$3.54 - $8.3 $150,425 - $352,691	-42,493 Reduced 3.72%	1,100,852 $4.45 Million
Q4 2021 Feb 14, 2022	SELL	$7.69 - $19.66 $11,358 - $29,037	-1,477 Reduced 0.13%	1,143,345 $9.16 Million

Q3 2021 Nov 12, 2021	BUY	$12.22 - $21.28 $2.41 Million - $4.2 Million	197,521 Added 20.85%	1,144,822 $22.1 Million
Q2 2021 Aug 13, 2021	BUY	$9.0 - $15.94 $8.53 Million - $15.1 Million	947,301 New	947,301 $13.1 Million

61.6K

Ticker PLXP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 29,137,700
Description
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other asp...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.